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Abstract
Background: ApolipoproteinA1(apoA1) is the major apoprotein constituent of high-density-
lipoprotein(HDL). The relationship of apoA1 -75 bp(M1-) allele polymorphism with lipoprotein
phenotype and cardiovascular diseae (CVD) remain unclear.
Overnight fasting blood samples were collected from a cohort of high-risk Omani population, 90
non-diabetic subjects and 149 type 2 diabetes mellitus (T2DM) subjects for genotype and
phenotype studies.
Results: The M1+ and M1- alleles frequencies were 0.808 and 0.192 for M1+ and M1-, respectively,
comparable to the frequency of apoA1 (M1+ and M1-) amongst a healthy Omani population, 0.788
and 0.212, respectively.
The frequencies of the hetero- and homozygous subjects for the MspI polymorphism at -75 (M1-)
of the apoA1 gene were in Hardy-Weinberg equilibrium.
The mean Lp(a) concentration was significantly higher(P = 0.02) in subjects carrying M1- allele
compared to M1+ allele of the APOA1 gene with an odd ratio of 2.3(95% CI, 1.13–14.3),
irrespective of gender and the diabetic status.
Conclusion: ApolipoproteinA1-75 G/A (M1-) polymorphism is relatively common and is positively
associated with Lp(a) and therefore, may confer a potential risk for cardiovascular disease (CVD).
Background
Apolipoprotein-A1 (apoA1) is the major apoprotein con-
stituent of HDL and an in vivo activator of lecithin-choles-
terol-acyltransferrase (LCAT). An inverse relationship has
been reported between the apoA1 and HDL and CVD in
the general population [1,2]. The protected effect of
apoA1 and HDL is mediated mainly through the promo-
tion of cholesterol efflux from peripheral cells. In addi-
tion, both HDL and apoA1 may also have antioxidant,
antithromobotic, and anti-inflammatory properties,
which could have important anti-atherogenic effects [3].
The plasma concentrations of apoA1 and HDL are
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number of environmental factors, e.g. smoking, alcohol
intake, exercise and lipid lowering medications [1,3]. A
strong genetic regulation of the concentration of HDL and
apoA1 has been established in twin and family studies,
the heritability of HDL concentration is around 40%
[3,4]. A number of studies had reported that the inter-
individual variations in plasma apoA1 and HDL are influ-
enced to a great extent by a common polymorphism of a
guanine (G) to adenine (A) substitution (G/A) at -75-bp
(M1-) in the apoA1 promoter region of the apoA1 gene
[5,6]. Numerous studies have looked into the above asso-
ciation with conflicting reports, part of the inconsistencies
could be due to the interaction of various environmental
and iatrogenic factors [4].
Previously, our group has reported the alleles frequency of
apoA1 gene among a healthy Omani population. The fre-
quency M1- allele was 22% [7]. This study was undertaken
to assess the influence of apoA1 -75 bp(M1-) allele poly-
morphism on lipoprotein phenotypes and Lp(a) among a
cohort of high-risk of Omani diabetic and non-diabetic
population.
Results
Lp(a), TG, and HDLc were positively skewed, therefore,
natural logarithms of the data were used in all parametric
significance testing.
The frequencies of the hetero- and homozygous subjects
for the MspI polymorphism at -75 (M1-) of the apoA1
gene were in Hardy-Weinberg equilibrium.
The M1+ and M1- alleles frequencies were 0.808 and
0.192 for M1+ and M1-, respectively. Table 1 represents
the influence of apoA -75 bp (M1-) gene polymorphism
on lipoprotein phenotype. The sample size of subjects car-
rying the homozygous minus alleles was small and there-
fore the hetero and homozygous minus alleles were
combined together in one group. Neither the demograph-
ics nor most of the lipoprotein parameters other than
Lp(a) have reached statistical significance. The mean
Lp(a) concentration was significantly higher (P = 0.02) in
subjects carrying the hetero or homozygous M1-+/-- gene
compared to M1++ gene with an odd ratio of 2.3 (95% CI,
1.13–14.3).
Women have significantly higher TChol, LDLc apoB,
HDLc, apoA1 and Lp(a) concentrations compared to
men. Despite the confounding influence of gender on var-
ious lipids and lipoproteins, Lp(a) was significantly
higher in subjects carrying the hetero or homozygous
minus allele (M1-+/-- gene) compared to the M1++ gene,
irrespective to gender (Table 2).
Lp(a) concentration was significantly higher in subjects
carrying the hetero or homozygous M1-+/-- gene compared
to the M1++ gene among women irrespective of the dia-
betic status. However, among men, it has reached statisti-
cal significance among the non-diabetic subjects only,
(Table 3).
Discussions
The G-to-A transition in the promoter region of apoA1
gene -75 (M1-) is relatively common, occurring in around
20% of the adult Omani diabetic and non-diabetic popu-
lation. Quite comparable to what our group have reported
previously on healthy Omani adult population.
The present study has revealed that the G-to-A transition
(M1-) in the promoter region of APOA1 gene was associ-
ated with a significantly higher Lp(a) concentration in
both diabetic and non-diabetic subjects irrespective of
gender. We underwent a Medline search; we were only
able to find one study where an association between the
apoA1 alleles polymorphism and Lp(a) was reported. This
study was on newborn babies from an Asian origin (Sin-
gapore, Chinese, Malays and Asian Indian) and on sam-
ples collected from cord plasma. They undertook this
study free of the confounding effect of environmental fac-
tors to determine the influence of apoA1 gene -75 (M1-)
polymorphism on apoA1 and HDL concentrations. To
their surprise no significant association was revealed
between the apoA1 polymorphism and the apoA1 and
HDL, however, a significant association was found
between the above polymorphic sites and Lp(a) in male
Asian Indians, and the apoA1 gene could account for 14%
of the variation in Lp(a) concentration [2].
The present study did not reveal any significant associa-
tion or influence of apoA1 polymorphism on the lipopro-
tein phenotype other than Lp(a). Partly due to the fact
that diabetes and metabolic syndrome are highly preva-
lent in Oman, according to a national survey, 20–30% of
the adult Omani population are either T2DM or have met-
abolic syndrome partly due to the increase in prevalence
of obesity, sedentary life and consanguinity rate. T2DM is
associated with dyslipidaemia that is characterized by
raised triglyceride, and low HDL cholesterol and there-
fore, it is tempting to speculate such confounding factors
could mask the influence of apoA1 genotyping on lipo-
protein phenotype [8-11]. Nevertheless, controversy exists
in the literature with regard to the influence of apoA1 pol-
ymorphism on HDL cholesterol, LDL and apoB. A signif-
icant associations between the M1- allele and elevated
HDL-cholesterol or apo A-I concentrations were reported
in Italian boys, but not girls [12]; in healthy, physically
active boys and young males from Belgium [13]; in Finn-
ish men [14] and in French-Canadian women [15]. In
contrast, no associations of the M1- allele with HDL-cho-Page 2 of 6
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et al [16], Lopez-Miranda et al [17], Mata et al [18], Car-
mena-Ramon et al [19], Akita et al [20] or Barre et al [21].
Moreover, Matsunaga et al in their study observed that
control subjects with the G/A genotype had significantly
lower plasma concentrations of apoA1 [24]. Pukkinen et
al and Heng et al. in their study they did not report any
association between the M1- allele of the APOA1 gene and
HDL/or apoA1 concentration in both diabetic and non-
diabetic subejcts [23]. In contrast Meng et al., reported a
lower concentration of HDLc and apoA1 among subjects
carrying M1- allele of the APOA1 gene [14].
Numerous studies have confirmed the pro- and anti-
atherogenic properties, respectively, of Lp(a) and apoA1
[24-26]. However, very few studies have looked into the
relations or impact of plasma concentration of apoA1 on
Lp(a). Animal studies have shown that the presence of
both transgenic apo(a) plus apoA1 results in animals pro-
tected against diet-induced atherosclerosis [27]. Chabra et
al. reported an association between apoA1 -75-bp and
IHD without any emphasis to the underlying cause, how-
ever, lower HDLc level was noticed in their studied group
[22]. In contrast, Petrovic et al. their study did not reveal
an association between ApoA1 polymorphism and IHD
[23]. The present study is the first in an adult population
that highlights the influence of apoA1 polymorphism on
Lp(a) concentration and the potential pro-atherogenic
role of M1- allele of the APOA1 gene. Future studies are
required on larger samples to confirm our findings and
perhaps look into some of the molecular mechanism that
could explain the interaction of apoA1 polymorphism
and Lp(a).
Conclusion
The G-to-A transition (M1-) in the promoter region of
APOA1 gene was significantly associated with higher
Lp(a) concentration in irrespective of gender and diabetic
status.
Subjects and methods
The institutional Ethics Committee approved the study
and all subjects gave their informed consent prior to par-
ticipating in this study. Ninety non-diabetic subjects (27
women and 63 men) and one hundred and forty nine dia-
betic subjects (53 women and 96 men) were recruited
from cardiac/lipid and diabetic clinics, respectively. All
patients had cardiovascular, respiratory, and central nerv-
ous systems examination. Blood pressure was measured
to the nearest even digit using a sphygmomanometer with
the subject in the sitting position after a 5–10 minutes rest
and considered hypertensive if the blood pressure was
equal or greater than 140/90 mmHg on two repeated
occasions or by 24 BP monitoring. Those on anti-hyper-
tensive therapy were also assumed to be hypertensive.
Diagnosis of T2DM was based on clinical characteristics;
prior history of use of oral hypoglycaemic agents, the pres-
ence of obesity, no history of ketosis, or strong family his-
tory of diabetes. World Health Organization criteria for
diagnosis of T2DM either by an abnormal oral glucose tol-
erance test (OGTT), two abnormal fasting blood glucose
(>7.0 mmol/L) or high HbA1c (>7%) were fulfilled by all
patients with type 2 diabetes. The proportions of T2DM
subjects on insulin, oral hypoglycaemic agents or dietary
control were 3%, 57% and 40%, respectively. History of
smoking, alcohol, exercise and prophylactic drugs (e.g. β-
blockers, aspirin, diuretics and sulphonylurias) was col-
lected. Patients were labeled CVD+ if they had a previous
myocardial infarction more than three months prior to
entry to the study or having stable angina pectoris and/or
they had a positive thallium stress test or coronary angi-
ogram. Exclusion criteria included myocardial infarction
within three months prior to entry to the study, uncon-
trolled thyroid disease (hypo or hyperthyroidism),
Table 1: The demographic and lipoprotein phenotypes based on apoA1 genotypes.
ApoA-1 genotypes P value
M1++ M1+-/--
Number 151 84
age 45.4(0.9) 45.2 (1.0) NS
BMI 30.7(0.6) 31.9 (1.6) NS
%CVD 28 27 NS
%T2DM 64 59 NS
%smoker 23 20 NS
Lp(a) g/l 0.200 (0.02) 0.285(0.03) 0.02
ApoA-1 (g/l) 1.19(0.02) 1.18(0.03) NS
HDLc mmol/l 1.20(0.03) 1.21(0.04) NS
TChol mmol/l 5.8 (0.12) 5.7(0.13) NS
LDLc (mmol/l) 3.8 (0.11) 3.8(0.12) NS
ApoB (g/l) 1.25(0.03) 1.25(0.03) NS
Triglycerides (mmol/l) 1.9 (0.16) 1.7(0.11) NAPage 3 of 6
(page number not for citation purposes)
Lipids in Health and Disease 2007, 6:19 http://www.lipidworld.com/content/6/1/19macro-proteinuria (positive urine protein dip-stick x2),
severe hepatic impairment or renal impairment (serum
creatinine level >114 (µmol/L), and those on lipid modi-
fying agents.
An overnight fasting blood samples were taken for meas-
urement of total cholesterol (TChol), triglycerides (TG),
HDL-cholesterol (HDLc), Lp(a) and apoA1 and apolipo-
protein B (ApoB). Cholesterol and triglycerides were
measured using timed endpoint enzymatic methods on
the Synchron CX system (Beckman).
ApoA1, apoB and Lp(a) were measured using rate neph-
elometric immunochemistry assay by IMMAGE system
(Beckman). Both the ApoB and ApoA-1 methods used
have been standardized according to the International
Federation of Clinical Chemistry. Reference material for
ApoB and ApoA-1 are lot SP3-07 and lot SP1-01, respec-
tively, which were approved by WHO [18]. Low density
lipoprotein cholesterol (LDLc) was calculated using the
Friedwald formula and was not calculated when TG level
was >4.4 mmol/L.
Polymerase chain reaction (PCR) was performed with a
modification of the Wang, Badenhop et al (1996)
method. Approximately 100 ng of genomic DNA was
amplified in a 25-µl reaction mixture containing 1.5 mM
Mgd2, 200 µM dNTPs, 10 pmol of each primer (forward
primer: 5'-AGGGACAGAGCTGATCC-TTGAACTCTTAG-
3'; reverse primer 5'TTAG-GGGACACCTACCCGTACAG-
GAAGAGCA-3'), AND 1 u Taq DNA polymerase (Gibco-
BRL). PCR conditions consisted of a 5-min initial
denaturation at 94°C, followed by 35 cycles of denatura-
tion at 94°C for 1 min, annealing at 60°C for 0.5 min,
and extension at 72°C for 0.5 min, with a final extension
at 72°C for 5 min. Fifteen microliters of the 434-bp PCR
product containing here MspI restriction sites at -75, +37,
and +83-bp of the APOA1 gene (Shoulders et al. 1983)
was digested with 3 U of MspI (Gibco BRL) overnight.
Accordingly, the digested PCR products gave 67-, 113-,
45-, and 209-bp fragments for the wild type and a combi-
nation of these fragments for the rare alleles. These frag-
ments were analyzed on 8% polyacrylamide gel stained
with ethidium bromide. The genotypes were determined
by comparing the relative mobilitys of DNA fragments
with reference to size molecular weight markers. The gen-
otypes and alleles were assigned the names adopted by
Wand, Liu et al (1996) [7].
Statistical Analysis
Data was analyzed with the Statistical Package for the
Social Sciences Software (SPSS version 10).
Descriptive analysis including the estimation of mean val-
ues and standard error of the mean (SEM) for continuous
variables were calculated. Skewed parameters were loga-
rithmically transformed and a parametric test was used.
The significance of differences for the means of plasma
Tchol, LDLc, HDLc, Triglycerides, apoB, apoA1, and Lp(a)
between genders and various groups were determined by
the t test or ANOVA as appropriate.
Chi square tests were used for establishing the relation-
ship between the lipid parameters and the apoA1 alleles.
The non-parametric Mann-Whitney test was used when
the underlying assumptions were not met.
ANOVA was performed to determine the effects of the
apoA1 gene polymorphism on the various lipid traits in
the different groups after adjustment for significant cov-
ariates. In order to verify whether age and sex were effec-





M1++ M1+-/-- P value M1++ M1+-/-- P value
Number 56 30 95 54
age 45.2 (1.2) 43.8(1.2) NS 45.7(1.09) 45.9(1.2) NS
BMI 29.6(4.5) 31(5.6) NS 29.7(0.7) 31.2(2.2) NS
%IHD 19 9 NS 34 38 NS
%T2DM 65 50 NS 63 65 NS
Lp(a) g/l 0.217(0.03) 0.368(0.07) 0.03 0.188(0.03) 0.247 (0.04) 0.048
ApoA-1 (g/l) 1.22(0.02) 1.26(0.04) NS 1.16(0.02) 1.14(0.02) NS
HDLc mmol/l 1.3 (0.05) 1.3(0.07) NS 1.15(0.03) 1.14(0.04) NS
TChol mmol/l 5.86(0.2) 5.98 (0.2) NS 5.76(0.15) 5.65(0.16) NS
LDLc (mmol/l) 3.9(0.2) 3.98 (0.2) NS 3.79(0.14) 3.68(0.14) NS
ApoB (g/l) 1.27(0.05) 1.27(0.06) NS 1.25(0.35) 1.23(0.3) NS
Triglycerides 
(mmol/l)
1.82(0.17) 1.50 (0.17) NS 2.09(0.23) 1.8(0.14) NSPage 4 of 6
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binary logistic regression models were fitted for each of
the lipid profiles after adjusting for age and sex as covari-
ates. To study the relationship between apoA1 polymor-
phism and IHD, two separate binary logistic regression
models were considered. Once the probability model for
IHD due to only apoA1 polymorphism was fitted and
then the model was refitted including all the six lipid pro-
files, for examining whether they were potentially effect
modifying variables or not. A p-value (two-tailed) of less
than 0.05 was considered as statistically significant.
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